查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926858

大腸直腸癌分子診斷市場按技術、產品類型、應用、生物標記、檢體類型和最終用戶分類－2026-2032年全球預測

Colorectal Cancer Molecular Diagnostics Market by Technology, Product Type, Application, Biomarker, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，大腸直腸癌分子診斷市場價值將達到 31.1 億美元，到 2026 年將成長至 33.1 億美元，到 2032 年將達到 49.4 億美元，複合年成長率為 6.82%。

關鍵市場統計數據
基準年 2025 31.1億美元
預計年份：2026年 33.1億美元
預測年份 2032 49.4億美元
複合年成長率 (%) 6.82%

本文簡要概述了正在改變大腸直腸癌分子診斷和治療路徑的臨床、技術和商業性因素。

分子診斷技術的進步正在重塑結直腸癌的臨床實踐，使檢測、預後和治療決策更加精準。過去十年，診斷模式已從基於形態學的評估轉向基於分子的策略，包括標靶基因組分析、微衛星不穩定性分析和循環腫瘤DNA分析。這些技術提高了臨床醫生對患者進行分層、識別可治療突變以及監測殘留病灶的能力，其靈敏度遠超傳統方法。

技術進步、生物資訊整合以及不斷變化的監管要求將如何融合，從而重新定義大腸直腸癌診斷的臨床效用和商業策略？

大腸直腸癌分子診斷領域正經歷一系列變革，這些變革的驅動力包括技術的成熟、臨床證據的不斷累積以及監管要求的不斷演變。次世代定序平台已超越其最初的應用階段，成為建構全面基因組分析方案的基礎；數位PCR和定量PCR持續為標靶突變檢測和微量殘存疾病監測提供靈敏且經濟高效的工具。同時，螢光原位雜合反應（FISH）和微陣列技術在特定的基因組背景下仍保持其獨特的效用，從而構建了一個多層次的診斷生態系統，能夠滿足廣泛和針對性強的臨床需求。

2025年關稅調整評估：診斷相關人員的供應鏈重組策略、區域製造決策與總擁有成本計算

2025年的關稅政策變化為那些維護跨境儀器、耗材和定序試劑供應鏈的公司帶來了特殊的複雜性。進口關稅和貿易措施的變化會影響資本財的價格波動、關鍵試劑的到岸成本以及製造地的經濟效益。對於依賴模組化全球供應鏈的製造商而言，即使是小幅的關稅上漲也可能需要重新評估籌資策略、庫存緩衝和合約條款，以保護利潤並維持對臨床檢查室和醫院系統的服務水準。

透過全面的細分分析，識別技術、產品、應用、生物標記、檢體類型和最終用戶之間的交集，從而指導策略性產品定位和臨床應用。

對市場區隔的深入理解揭示了結直腸癌分子診斷領域中臨床需求、技術能力和商業性機會的交匯點。從技術面來看，該領域涵蓋螢光原位雜合反應(FISH)、微陣列、次世代定序(NGS) 和聚合酵素鏈鎖反應(PCR) 技術。次世代定序技術本身已擴展到標靶定序、全EXOME定序和全基因測序，每種技術在深度、廣度和成本方面各有優劣。聚合酵素鏈鎖反應(PCR) 技術，包括數位 PCR 和定量 PCR，對於靈敏的靶向突變檢測以及那些優先考慮快速結果和易於分析的應用仍然至關重要。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的診斷技術應用路徑、監管應對措施和商業化選擇。

區域趨勢對分子診斷的普及率、監管路徑和商業模式有著深遠的影響。在美洲，成熟的臨床網路和大規模參考實驗室正在推動複雜基因組檢測的早期應用，並將伴隨診斷整合到癌症治療路徑中。該地區的新參與企業往往面臨支付方結構分散和機構採購慣例各異的問題，即使臨床指南越來越建議分子檢測，也可能導致患者獲得檢測的機會不均等。

策略競爭考察：揭示平台整合商、試劑專家、生物資訊學供應商和檢測實驗室網路如何塑造市場定位和合作機會

大腸直腸癌分子診斷領域的競爭格局呈現出多元化的組織頻譜，包括成熟的平台製造商、試劑專家、生物資訊公司、參考檢查室網路以及靈活的Start-Ups公司。平台製造商正致力於開發整合解決方案，將定序儀和PCR系統與檢驗的耗材和判讀軟體結合，以降低臨床檢查室採用這些技術的門檻。試劑和試劑盒供應商則優先考慮分析性能、供應可靠性和簡化的工作流程，這些工作對於尋求穩定日常檢測量和符合法規要求的檢查室至關重要。

透過提供產品整合、供應鏈韌性、證據產生和支付方參與等方面的切實可行的策略建議，加速臨床應用和商業性成功。

產業領導者應檢驗將分析的穩健性與簡化的臨床工作流程結合的整合產品，並將驗證後的儀器、耗材和軟體整合為統一的解決方案。投資於能夠降低檢查室設置複雜性並提供清晰解讀指南的承包檢測包，將有助於降低醫院和診斷中心採用這些產品的門檻。此外，企業還應努力產生將檢測結果與可操作的治療決策和可證實的患者療效聯繫起來的臨床證據，從而增強報銷理由並提升臨床醫生的信心。

採用嚴謹的混合調查方法，結合專家訪談、系統性文獻回顧和交叉檢驗的品質檢查，以確保臨床和商業性相關性。

本分析的調查方法結合了定性專家訪談和對已發表的科學文獻、監管文件以及不斷更新的臨床指南的系統性綜合分析。關鍵輸入包括對臨床腫瘤學、分子病理學、生物資訊學和檢查室運營等領域的關鍵行業專家進行結構化訪談，以確定實際應用中的促進因素、營運限制和未滿足的需求。這些專家見解與同儕審查的研究和監管通告進行交叉比對，以確保其與目前的臨床實踐和核准框架保持一致。

本文綜合分析了關鍵見解，重點闡述了技術成熟度、證據產生、供應鏈韌性和區域策略的交匯點，這些因素共同決定了市場成功。

大腸直腸癌分子診斷正處於技術進步與臨床應用價值驗證的關鍵節點。次世代定序和先進的PCR技術等互補優勢，支持從伴隨診斷到微量殘存疾病監測等廣泛的臨床應用。儘管日趨成熟的生物資訊學和解讀服務顯著提升了分子檢測結果的臨床效用，但區域監管差異和支付方差異仍影響其應用前景。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依技術分類的大腸直腸癌分子診斷市場

  • 螢光原位雜合反應
  • 微陣列
  • 次世代定序
    • 標靶定序
    • 全外EXOME定序
    • 全基因測序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR

9. 依產品類型分類的大腸直腸癌分子診斷市場

  • 裝置
    • PCR系統
    • 序列器
  • 試劑盒和試劑
  • 軟體服務
    • 生物資訊服務
    • 數據分析軟體

第10章 依應用分類的大腸直腸癌分子診斷市場

  • 伴隨診斷
  • 預測性測試
  • 預後測試
  • 殘留疾病監測

第11章 大腸直腸癌分子診斷市場（依生物標記分類）

  • BRAF
  • KRAS
  • 微衛星不穩定性
  • NRAS

第12章 依檢體類型分類的大腸直腸癌分子診斷市場

  • 血
    • 電漿
    • 血清
  • 航班
  • 組織

第13章 大腸直腸癌分子診斷市場（依最終用戶分類）

  • 學術研究機構
  • 診斷中心
  • 醫院和診所
  • 參考檢驗機構

第14章 大腸直腸癌分子診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 大腸直腸癌分子診斷市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國大腸直腸癌分子診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國大腸直腸癌分子診斷市場

第18章：中國大腸直腸癌分子診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4F7A6D4FF33B

The Colorectal Cancer Molecular Diagnostics Market was valued at USD 3.11 billion in 2025 and is projected to grow to USD 3.31 billion in 2026, with a CAGR of 6.82%, reaching USD 4.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.11 billion
Estimated Year [2026] USD 3.31 billion
Forecast Year [2032] USD 4.94 billion
CAGR (%) 6.82%

A succinct orientation to the evolving clinical, technological, and commercial forces transforming colorectal cancer molecular diagnostics and care pathways

Advances in molecular diagnostics are reshaping clinical practice for colorectal cancer by enabling more precise detection, prognosis, and therapeutic decision-making. Over the last decade, diagnostic paradigms have shifted from morphology-driven assessments toward molecularly informed strategies that incorporate targeted genomic profiling, microsatellite instability evaluation, and circulating tumor DNA analysis. These capabilities are enhancing the clinician's ability to stratify patients, identify actionable alterations, and monitor residual disease with greater sensitivity than conventional approaches.

Transitioning from laboratory innovation to routine clinical use requires alignment across technology platforms, clinical validation pathways, regulatory frameworks, and payer engagement. As such, stakeholders spanning instrument manufacturers, kit and reagent suppliers, bioinformatics firms, clinical laboratories, and healthcare providers must coordinate efforts to ensure robustness, reproducibility, and clinical utility. The increasing convergence of sequencing platforms, digital PCR modalities, and integrated bioinformatics is lowering time-to-result and improving the granularity of molecular readouts, which in turn supports personalized treatment pathways and more efficient clinical workflows.

Given these dynamics, an executive-level synthesis of technological trajectories, adoption barriers, and use-case evidence is essential for strategic planning. This summary frames the prevailing scientific trends, commercial inflection points, and practical considerations that industry leaders and health-system decision-makers should weigh when prioritizing investments or forming collaborative alliances in the colorectal cancer molecular diagnostics arena.

How converging technology advances, integrated bioinformatics, and shifting regulatory expectations are redefining clinical utility and commercial strategies in colorectal cancer diagnostics

The landscape for colorectal cancer molecular diagnostics is experiencing a series of transformative shifts driven by technological maturation, expanding clinical evidence, and evolving regulatory expectations. Next-generation sequencing platforms have moved beyond early-adopter use to form the backbone of comprehensive genomic profiling programs, while digital PCR and quantitative PCR have continued to provide sensitive, cost-efficient tools for targeted mutation detection and minimal residual disease monitoring. Concurrently, fluorescence in situ hybridization and microarray technologies retain niche utility for specific genomic contexts, creating a layered diagnostic ecosystem that supports both broad and focused clinical questions.

Alongside platform evolution, bioinformatics and data analytics have emerged as critical differentiators. The ability to integrate variant calling, copy-number assessment, and clinically annotated interpretation at scale is accelerating clinical utility and enabling laboratories to deliver actionable reports in clinically relevant timeframes. In parallel, advances in liquid biopsy methodologies allow serial sampling via plasma and serum, making longitudinal monitoring of disease dynamics clinically feasible and less invasive. These shifts are prompting diagnostics providers to develop more integrated solutions that combine hardware, chemistry, and software in validated workflows.

Regulatory frameworks and payer expectations are adapting in response to growing clinical evidence, but heterogeneity in regional pathways and reimbursement policies continues to influence adoption rates. As stakeholders respond to these shifts, strategic imperatives include prioritizing high-value applications such as companion diagnostics for targeted therapies, robust analytical and clinical validation for residual disease assays, and investment in scalable laboratory operations and data infrastructure to support broader clinical deployment. The cumulative effect is a market environment that rewards interoperability, clinical outcome linkage, and proof of utility over isolated technical capability alone.

Assessment of 2025 tariff adjustments that are reshaping supply chain strategies, regional manufacturing decisions, and total-cost-of-ownership calculations for diagnostics stakeholders

Tariff policy shifts in 2025 have introduced tangible complexity for companies that maintain cross-border supply chains for instruments, consumables, and sequencing reagents. Changes in import duties and trade measures affect capital equipment pricing dynamics, the landed cost of critical reagents, and the economics of manufacturing footprints. For manufacturers that depend on modular global supply chains, even modest tariff increases can require re-evaluation of sourcing strategies, inventory buffers, and contract terms to protect margins and maintain service levels for clinical laboratories and hospital systems.

In response, many organizations are reassessing their operational models to increase regional resilience. Potential strategies include nearshoring production of high-volume consumables, expanding regional assembly hubs for instruments, and negotiating long-term supply agreements that hedge against tariff volatility. These adjustments aim to stabilize pricing for end users and reduce lead-time exposure, but they also require capital allocation and careful regulatory alignment to ensure that product specifications and quality management systems remain consistent across manufacturing sites.

Moreover, tariffs can indirectly influence innovation decisions by altering the economics of bringing new assays or platforms to market. Developers may prioritize software-driven differentiation and consumables with higher gross margins to offset increased import costs for hardware, or they may focus on strategic partnerships with local manufacturers to maintain competitive pricing. For clinical laboratories and institutional purchasers, procurement teams will likely place greater emphasis on total-cost-of-ownership analyses, including maintenance, consumables, and potential duty impacts, when evaluating instrument and assay purchases. In sum, tariff changes in 2025 have amplified the need for supply chain agility and strategic sourcing in the molecular diagnostics value chain.

Comprehensive segmentation analysis identifying technology, product, application, biomarker, sample type, and end-user intersections that inform strategic product positioning and clinical adoption

A nuanced understanding of market segmentation reveals where clinical demand, technological capability, and commercial opportunity intersect within colorectal cancer molecular diagnostics. Based on technologies, the field spans fluorescence in situ hybridization, microarray, next-generation sequencing, and polymerase chain reaction techniques. Next-generation sequencing itself is deployed across targeted sequencing, whole exome sequencing, and whole genome sequencing approaches, each offering distinct trade-offs between depth, breadth, and cost. Polymerase chain reaction modalities, including digital PCR and quantitative PCR, remain essential for highly sensitive, targeted mutation detection and for applications where rapid turnaround and lower analytical complexity are priorities.

When framed by product type, the ecosystem includes instruments, kits and reagents, and software services. Instruments commonly comprise PCR systems and sequencers that form the hardware backbone of both centralized and decentralized laboratories. Kits and reagents supply the chemistry necessary for reliable performance, while software services encompass bioinformatics services and data analysis software that translate raw signals into clinically meaningful insights. This integration of hardware, chemistry, and informatics is a recurring theme across commercial models and is pivotal in driving laboratory workflow efficiency and report interpretability.

Application-oriented segmentation highlights areas where clinical evidence is driving adoption. Companion diagnostics continue to be a high-priority application due to their direct linkage to targeted therapies, whereas predictive and prognostic testing expand personalized treatment selection and risk stratification. Residual disease monitoring is gaining traction as clinicians seek validated methods to detect minimal residual disease and to inform adjuvant therapy decisions. Biomarker segmentation emphasizes clinically actionable targets such as BRAF, KRAS, microsatellite instability, and NRAS, each representing specific diagnostic and therapeutic decision points in colorectal cancer management.

Sample type considerations influence upstream and downstream assay design. Diagnostic workflows accommodate blood-based testing, including plasma and serum, as well as stool and tissue samples. The rise of liquid biopsy approaches based on plasma has implications for assay sensitivity, pre-analytical handling, and longitudinal monitoring protocols. Finally, end-user segmentation delineates the operational contexts in which these technologies are deployed: academic research institutes drive innovation and validation studies; diagnostic centers and reference laboratories scale clinical testing; and hospitals and clinics integrate results into patient care pathways. Collectively, these segmentation lenses inform product development priorities, commercialization strategies, and partnership models for stakeholders seeking to align offerings with clinical demand.

Regional dynamics shaping diagnostic adoption pathways, regulatory navigation, and commercialization choices across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

Regional dynamics exert a profound influence on adoption velocities, regulatory pathways, and commercial models for molecular diagnostics. In the Americas, established clinical networks and large reference laboratories facilitate early adoption of complex genomic assays and the integration of companion diagnostics into oncology treatment pathways. Market participants in this region often contend with fragmented payer landscapes and institution-specific procurement practices, which can create variability in access even as clinical guidelines increasingly endorse molecular testing.

In Europe, the Middle East & Africa region, heterogeneity is pronounced across regulatory frameworks, reimbursement environments, and healthcare infrastructure. Certain European markets are characterized by centralized evaluation systems and national testing recommendations that can accelerate standardized adoption, while other markets in the broader region require localized validation and tailored commercial approaches. Manufacturers seeking presence across these diverse jurisdictions must balance regulatory harmonization with flexible market entry strategies that reflect regional reimbursement and laboratory capacity.

The Asia-Pacific region demonstrates a blend of rapid technology uptake in urban centers alongside ongoing development of diagnostic infrastructure in emerging markets. Public health initiatives and growing oncology patient volumes are encouraging investment in molecular diagnostic capabilities, while regional manufacturing hubs are expanding to serve both local and export demand. Across all regions, differences in sample logistics, laboratory accreditation practices, and clinician familiarity with genomic reports inform go-to-market planning. Therefore, regional strategies should weigh clinical guidelines, reimbursement pathways, supply chain resilience, and potential partnerships with local diagnostic networks to optimize adoption and scale.

Strategic competitive insights revealing how platform integrators, reagent specialists, bioinformatics providers, and laboratory networks are shaping market positioning and alliance opportunities

Competitive positioning in colorectal cancer molecular diagnostics reflects a spectrum of organizational archetypes that include established platform manufacturers, reagent specialists, bioinformatics firms, reference laboratory networks, and nimble startups. Platform manufacturers are investing in integrated solutions that couple sequencers or PCR systems with validated consumables and interpretation software to reduce implementation friction for clinical laboratories. Reagent and kit providers emphasize analytical performance, supply reliability, and streamlined workflows, which are critical for laboratories seeking consistent daily throughput and regulatory compliance.

Bioinformatics and data analytics companies are becoming indispensable partners, offering cloud-enabled variant interpretation, automation of reporting, and clinical decision support that can differentiate product offerings. Reference laboratories and centralized testing networks continue to play a dual role as both customers and collaborators; they often provide clinical validation studies, drive adoption through clinician engagement, and serve as launch partners for new assays. Emerging startups frequently focus on niche innovations-such as ultra-sensitive circulating tumor DNA assays or novel biomarker panels-that can be licensed or acquired by larger incumbents seeking to expand their portfolios.

Strategic alliances between technology vendors and clinical institutions are proving effective in bridging the gap between analytical performance and demonstrated clinical utility. These collaborations accelerate evidence generation, support payer discussions, and facilitate broader clinician acceptance. Overall, companies that align product development with scalable laboratory workflows, robust data interpretation, and clear clinical use cases will be best positioned to capture long-term value in a competitive environment.

Actionable strategic recommendations for product integration, supply chain resilience, evidence generation, and payer engagement to accelerate clinical adoption and commercial success

Industry leaders should prioritize integrated product offerings that marry analytical robustness with streamlined clinical workflows, ensuring that instruments, consumables, and software are validated as coherent solutions. Investing in turnkey assay packages that reduce laboratory setup complexity and provide clear interpretive guidance will lower adoption barriers for hospitals and diagnostic centers. Furthermore, companies should pursue clinical evidence generation that links assay results to actionable treatment decisions and demonstrable patient outcomes to strengthen reimbursement arguments and clinician trust.

Operationally, strengthening supply chain resilience is essential in an environment affected by tariff volatility and component shortages. This can be achieved through diversification of manufacturing locations, strategic inventory management, and long-term supplier agreements that include quality and delivery commitments. From a commercial standpoint, forming partnerships with reference laboratories and academic centers can accelerate validation and market entry while providing a channel for clinician education. Additionally, embedding advanced bioinformatics and decision-support tools into product offerings will enhance the clinical value proposition and enable scalable interpretation across diverse laboratory settings.

Finally, engaging proactively with regional regulatory bodies and payer stakeholders to align on evidence requirements and reimbursement pathways will reduce time-to-adoption. Manufacturers should build flexible commercialization playbooks that account for regional heterogeneity, including tailored pricing models, local validation packages, and collaborative post-market evidence collection. By executing these strategic imperatives, industry leaders can convert technological capability into sustained clinical and commercial impact.

Rigorous mixed-methods research approach combining expert interviews, systematic literature synthesis, and cross-validated quality checks to ensure clinical and commercial relevance

The research methodology underpinning this analysis combined qualitative expert engagement with systematic synthesis of public-domain scientific literature, regulatory documentation, and clinical guideline evolution. Primary inputs included structured interviews with key opinion leaders across clinical oncology, molecular pathology, bioinformatics, and laboratory operations to surface real-world adoption drivers, operational constraints, and unmet clinical needs. These expert perspectives were contextualized against peer-reviewed studies and regulatory notices to ensure alignment with current clinical practice and approval frameworks.

Secondary analysis involved a methodical review of technology performance characteristics, assay validation literature, and published clinical utility data to identify consistent trends and evidence gaps. Comparative evaluation of platform architectures, pre-analytical requirements for different sample types, and bioinformatics workflows informed assessments of integration complexity and laboratory suitability. Cross-validation of insights through multiple data sources and stakeholder voices was applied to reduce bias and enhance the robustness of conclusions.

Quality assurance measures included triangulation of primary and secondary findings, iterative review by subject-matter experts, and alignment checks against contemporary clinical guidelines and consensus statements. The research process prioritized transparency, reproducibility, and clinical relevance to produce actionable intelligence for business strategy and product development decisions in the colorectal cancer molecular diagnostics domain.

Synthesis of critical takeaways highlighting the intersection of technology maturation, evidence generation, supply chain resilience, and regional strategy that will dictate marketplace success

Colorectal cancer molecular diagnostics occupies a pivotal junction between advancing technological capability and the imperative to demonstrate clinical impact. Technologies such as next-generation sequencing and advanced PCR modalities offer complementary strengths that support a range of clinical applications from companion diagnostics to minimal residual disease monitoring. The maturation of bioinformatics and interpretation services has materially improved the clinical utility of molecular results, yet regional regulatory heterogeneity and payer variability continue to shape adoption trajectories.

Strategic responses to 2025 tariff changes and supply chain pressures underscore the need for operational agility, regional manufacturing considerations, and total-cost-of-ownership thinking. Companies that prioritize integrated solutions-bringing together reliable instruments, high-performing consumables, and validated interpretation software-will reduce implementation friction for laboratories and clinicians. Collaborative evidence generation with academic centers and reference laboratories will accelerate real-world validation and strengthen reimbursement discussions.

In closing, the path to broader clinical adoption lies in aligning technological innovation with demonstrable patient benefit, resilient supply chains, and pragmatic commercialization strategies that respect regional diversity. Stakeholders that successfully bridge these dimensions will be best positioned to influence care pathways and to realize long-term clinical and commercial value in colorectal cancer molecular diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Molecular Diagnostics Market, by Technology

  • 8.1. Fluorescence In Situ Hybridization
  • 8.2. Microarray
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. Polymerase Chain Reaction
    • 8.4.1. Digital PCR
    • 8.4.2. Quantitative PCR

9. Colorectal Cancer Molecular Diagnostics Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. PCR Systems
    • 9.1.2. Sequencers
  • 9.2. Kits Reagents
  • 9.3. Software Services
    • 9.3.1. Bioinformatics Services
    • 9.3.2. Data Analysis Software

10. Colorectal Cancer Molecular Diagnostics Market, by Application

  • 10.1. Companion Diagnostics
  • 10.2. Predictive Testing
  • 10.3. Prognostic Testing
  • 10.4. Residual Disease Monitoring

11. Colorectal Cancer Molecular Diagnostics Market, by Biomarker

  • 11.1. BRAF
  • 11.2. KRAS
  • 11.3. Microsatellite Instability
  • 11.4. NRAS

12. Colorectal Cancer Molecular Diagnostics Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Plasma
    • 12.1.2. Serum
  • 12.2. Stool
  • 12.3. Tissue

13. Colorectal Cancer Molecular Diagnostics Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals Clinics
  • 13.4. Reference Laboratories

14. Colorectal Cancer Molecular Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Colorectal Cancer Molecular Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Colorectal Cancer Molecular Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Colorectal Cancer Molecular Diagnostics Market

18. China Colorectal Cancer Molecular Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Agilent Technologies, Inc.
  • 19.6. Bio-Rad Laboratories, Inc.
  • 19.7. Exact Sciences Corporation
  • 19.8. F. Hoffmann-La Roche Ltd
  • 19.9. Guardant Health, Inc.
  • 19.10. Hologic, Inc.
  • 19.11. Illumina, Inc.
  • 19.12. Myriad Genetics, Inc.
  • 19.13. Qiagen N.V.
  • 19.14. Sysmex Corporation
  • 19.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KITS REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PREDICTIVE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PROGNOSTIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BRAF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY KRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROSATELLITE INSTABILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NRAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 229. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 233. GCC COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 261. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 264. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE SERVICES, 2018-2032 (USD MILLION)
  • TABLE 265. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 267. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 269. G7 COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 273. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 274. NATO COLORECTAL CANCER MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO COLORECTAL